{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:27:53Z","timestamp":1784770073498,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.euroneuro.2017.06.009","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T06:30:34Z","timestamp":1498199434000},"page":"940-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Escitalopram plasma levels and antidepressant response"],"prefix":"10.1016","volume":"27","author":[{"given":"Vincenzo","family":"Florio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alois","family":"Saria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.06.009_bib1","unstructured":"Association, A.P., 2000. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC."},{"key":"10.1016\/j.euroneuro.2017.06.009_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroimage.2013.10.002","article-title":"Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET","volume":"88","author":"Baldinger","year":"2014","journal-title":"NeuroImage"},{"key":"10.1016\/j.euroneuro.2017.06.009_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jad.2015.09.033","article-title":"Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study","volume":"189","author":"Balestri","year":"2016","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.euroneuro.2017.06.009_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.009_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bjp.174.4.297","article-title":"Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials","volume":"174","author":"Bollini","year":"1999","journal-title":"Br. J. psychiatry: J. Ment. Sci."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.06.009_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/070674371405900202","article-title":"From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment","volume":"59","author":"Fabbri","year":"2014","journal-title":"Can. J. psychiatry Rev. Can. Psychiatr."},{"issue":"4","key":"10.1016\/j.euroneuro.2017.06.009_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br. J. Soc. Clin. Psychol."},{"issue":"6","key":"10.1016\/j.euroneuro.2017.06.009_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2017.06.009_bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1176\/appi.ajp.2015.15030331","article-title":"Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder","volume":"173","author":"Jakubovski","year":"2016","journal-title":"Am. J. psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2017.06.009_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/YIC.0b013e32832a8ec8","article-title":"Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram","volume":"24","author":"Kasper","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2017.06.009_bib11","first-page":"S39","article-title":"Tolerability and safety: essentials in antidepressant pharmacotherapy","volume":"57","author":"Lader","year":"1996","journal-title":"J. Clin. psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2017.06.009_bib12","first-page":"1073","article-title":"Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry","volume":"44","author":"Linder","year":"1998","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.euroneuro.2017.06.009_bib13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study","volume":"161","author":"Meyer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.06.009_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BFb0067700","article-title":"The Levenberg\u2013Marquardt algorithm: implementation and theory","volume":"630","author":"Mor\u00e9","year":"1977","journal-title":"Lect. Notes Math."},{"issue":"3","key":"10.1016\/j.euroneuro.2017.06.009_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JCP.0b013e318218f503","article-title":"Association between citalopram serum levels and clinical improvement of patients with major depression","volume":"31","author":"Ostad Haji","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2017.06.009_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.31887\/DCNS.2008.10.4\/gipapakostas","article-title":"Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder","volume":"10","author":"Papakostas","year":"2008","journal-title":"Dialog-. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.euroneuro.2017.06.009_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0706743716660034","article-title":"Updated CANMAT guidelines for treatment of major depressive disorder","volume":"61","author":"Patten","year":"2016","journal-title":"Can. J. Psychiatry Rev. Can. Psychiatr."},{"issue":"3","key":"10.1016\/j.euroneuro.2017.06.009_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/YIC.0000000000000114","article-title":"Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants","volume":"31","author":"Paulzen","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.06.009_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1503\/jpn.100059","article-title":"Pharmacogenetics of antidepressant response","volume":"36","author":"Porcelli","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"issue":"9","key":"10.1016\/j.euroneuro.2017.06.009_bib20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1517\/17425255.2011.597740","article-title":"Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism","volume":"7","author":"Porcelli","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.06.009_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00007691-200004000-00001","article-title":"Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?","volume":"22","author":"Rasmussen","year":"2000","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.euroneuro.2017.06.009_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v58n0206d","article-title":"SSRI optimal dose remains at issue","volume":"58","author":"Rifkin","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2017.06.009_bib23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00216-007-1320-1","article-title":"Current role of LC-MS in therapeutic drug monitoring","volume":"388","author":"Saint-Marcoux","year":"2007","journal-title":"Anal. Bioanal. Chem."},{"issue":"Suppl. 6","key":"10.1016\/j.euroneuro.2017.06.009_bib24","first-page":"S16","article-title":"Treatment-resistant depression","volume":"67","author":"Souery","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2017.06.009_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-011-2463-5","article-title":"Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action","volume":"219","author":"Zhong","year":"2012","journal-title":"Psychopharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T23:54:43Z","timestamp":1659138883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17302869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924977X17302869"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.06.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Escitalopram plasma levels and antidepressant response","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}